Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 2 de 2
1.
Biomed Pharmacother ; 153: 113478, 2022 Sep.
Article En | MEDLINE | ID: mdl-36076580

Valencene (VLN) is a sesquiterpene found in juices and essential oils of citrus species such as Cyperus rotundus. Considering the evidence that this species has anti-inflammatory effects, the present study aims to evaluate the anti-inflammatory activity of VLN in vivo and in silico. Swiss mice (n = 6) were orally treated according to their treatment groups as follows: VLN (10, 100 or 300 mg/kg), negative control (0.9% saline), and positive controls (indomethacin 25 mg/kg or promethazine 6 mg/kg). The anti-inflammatory activity was evaluated in murine models of acute and chronic inflammation. The inhibition of acute inflammation was evaluated in models of paw edema induced by different inflammatory agents (carrageenan, dextran, histamine, and arachidonic acid (AA)) and carrageenan-induced pleurisy and peritonitis. The modulation of chronic inflammation was evaluated in a granuloma model induced cotton pellets implantation. The interaction with inflammatory targets was evaluated in silico using molecular docking analysis. The administration of VLN to challenged mice significantly inhibited paw edema formation with no significant difference between the administered doses. The compound also reduced albumin extravasation, leukocyte recruitment, and the production of myeloperoxidase (MPO), IL-1ß, and TNF-α in both pleural and peritoneal lavages. According to the mathematical-statistical model observed in silico analysis, this compound has favorable energy to interact with the cyclooxygenase enzyme (COX-2) and the histamine 1 (H1) receptor. Finally, animals treated with the sesquiterpene showed a reduction in both granuloma weight and concentration of total proteins in a chronic inflammation model. Given these findings, it is concluded that NLV presents promising pharmacological activity in murine models of acute and chronic inflammation.


Anti-Inflammatory Agents, Non-Steroidal , Sesquiterpenes , Animals , Anti-Inflammatory Agents/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Carrageenan/therapeutic use , Cyclooxygenase 2 , Edema/chemically induced , Edema/drug therapy , Granuloma/drug therapy , Histamine , Inflammation/metabolism , Mice , Molecular Docking Simulation , Plant Extracts/pharmacology , Sesquiterpenes/pharmacology
2.
Neuroscience ; 358: 158-169, 2017 09 01.
Article En | MEDLINE | ID: mdl-28673718

Chronic musculoskeletal pain is one of the main symptoms found in Fibromyalgia with unclear etiology and limited pharmacological treatment. The aim of this study was to complex LIM in ß-cyclodextrin (LIM-ßCD) and then evaluate its antihyperalgesic effect in an animal model of chronic musculoskeletal pain. Differential scanning calorimetry and scanning electron microscopy was used for the characterization of the inclusion complex. Male Swiss mice were used for experimental procedures where mechanical hyperalgesia, thermal hyperalgesia, muscular strength, Fos immunofluorescence was studied after induction of hyperalgesia. Mechanism of action was also investigated through tail flick test and capsaicin-induced nociception. Endothermic events and morphological changes showed that the slurry complex method was the best method for the complexation. After induction of hyperalgesia, the oral administration of LIM-ßCD (50mg/kg) significantly increased the paw withdrawal threshold compared to uncomplexed limonene. Fos immunofluorescence showed that both compounds significantly decreased the number of Fos-positive cells in the dorsal horn. In nociceptive tests, FLU was able to reverse the antinociceptive effect of LIM-ßCD. After intraplantar administration of capsaicin, LIM was able to significantly decrease time to lick. LIM-ßCD has antihyperalgesic action superior to its uncomplexed form, with possible action in the dorsal horn of the spinal cord. These results suggest the possible applicability of LIM, uncomplexed or complexed with ßCD, in conditions such as FM and neuropathic pain, for which there are currently only limited pharmacological options.


Analgesics/therapeutic use , Cyclohexenes/therapeutic use , Musculoskeletal Pain/drug therapy , Musculoskeletal Pain/pathology , Proto-Oncogene Proteins c-fos/metabolism , Spinal Cord/drug effects , Terpenes/therapeutic use , beta-Cyclodextrins/therapeutic use , Animals , Capsaicin/toxicity , Disease Models, Animal , Drug Combinations , Drug Interactions , GABA Agents/therapeutic use , Hyperalgesia/drug therapy , Hyperalgesia/etiology , Limonene , Male , Mice , Muscle Strength/drug effects , Muscle Strength/physiology , Musculoskeletal Pain/chemically induced , Nociception/drug effects , Pain Measurement/drug effects , Pain Measurement/methods , Pain Threshold/drug effects , Spinal Cord/metabolism , Statistics, Nonparametric
...